Instructor in Medicine, Dana-Farber Cancer Institute

Hematology

David D'Adamo practices Hematology. He attended Mount Sinai School of Medicine. David D'Adamo is also a published doctor. He has 24 paper published. The most recent paper is: rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral.

Publications

---

• Eribulin versus dacarbazine in previously treated patients with advanced lipoSarcoma or leiomyoSarcoma: a randomised, open-label, multicentre, phase 3 trial.
• Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal Tumors.
• Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angioSarcomas.
• Integrating novel therapies into the treatment of sarcoma: a multidisciplinary approach--introDuction.
• Appraising the current role of chemotherapy for the treatment of Sarcoma.
• An Emerging Entity: Pancreatic AdenoCarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions.
• Activity of sorafenib against desmoid tumor/deep fibromatoses.
• Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
• Clinical outcomes of Systemic therapy for patients with deep fibromatosis (desmoid tumor).
• Chemotherapy in clear cell Sarcoma.
• Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor Sarcomas.
• Phase II study of sorafenib in patients with metastatic or recurrent Sarcomas.
• Extraskeletal myxoid chondroSarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy.
• Sarcoma.
• Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue Sarcomas.
• Phase II study of olaparib in patients with refractory Ewing Sarcoma following failure of standard chemotherapy.
• A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.
• rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral.
• Advances in the treatment of gastrointestinal stromal tumor.
• Pure primary prostatic osteoSarcoma arising in a non-irradiated prostate.
• Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
• A retrospective Analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas.
• Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenoCarcinoma.

Procedures Preformed

---

• Thoracentesis

Conditions Treated

---

• Adrenal Gland Cancer
• Anal and Rectal Cancer
• Anemia
• Bile Duct Cancer
• View All

Doctors Specialties

---

• Medical Oncology
• Oncology
• Hematology

Accepted Insurances

---

Education

---

• Memorial Sloan-Kettering Cancer Center
• Mount Sinai School of Medicine
• NYU School of Medicine

Hospital

---

• Dana-Farber Cancer Institute
• Memorial Sloan-Kettering Cancer Center

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Rushdia Z. Yusuf, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert G. Delage, MD
	Dr. Michal Bar-Natan, MD This Doctor is OpenDoctor Recommended.
	Dr. Matthew D. Hellmann, MD This Doctor is OpenDoctor Recommended.
	Dr. David B. Sykes, MD This Doctor is OpenDoctor Recommended.
	Dr. Christopher S. Lathan, MD This Doctor is OpenDoctor Recommended.
	Dr. Sarah Nikiforow, MD This Doctor is OpenDoctor Recommended.
	Dr. Jill N. Allen, MD
	Dr. Lecia V. Sequist, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Claudia E. Paba, MD This Doctor is OpenDoctor Recommended.
	Dr. Benjamin B. Freeman, MD This Doctor is OpenDoctor Recommended.
	Dr. Marjory Charlot, MD This Doctor is OpenDoctor Recommended.
	Vaishali H. Sanchorawala, MB This Doctor is OpenDoctor Recommended. This doctor has more publications

---

Doctor Directory | TOS | twitter | FB | Angel | blog